These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology. Coskuner-Weber O; Uversky VN Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364151 [TBL] [Abstract][Full Text] [Related]
4. The Parkinson's disease-associated H50Q mutation accelerates α-Synuclein aggregation in vitro. Ghosh D; Mondal M; Mohite GM; Singh PK; Ranjan P; Anoop A; Ghosh S; Jha NN; Kumar A; Maji SK Biochemistry; 2013 Oct; 52(40):6925-7. PubMed ID: 24047453 [TBL] [Abstract][Full Text] [Related]
5. Parkinson's disease-associated mutations in α-synuclein alters its lipid-bound state. Maltseva S; Kerr D; Turke M; Adams EJ; Lee KYC Biophys J; 2024 Jun; 123(12):1610-1619. PubMed ID: 38702883 [TBL] [Abstract][Full Text] [Related]
6. Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein. Uversky VN; Eliezer D Curr Protein Pept Sci; 2009 Oct; 10(5):483-99. PubMed ID: 19538146 [TBL] [Abstract][Full Text] [Related]
7. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations. Sahay S; Ghosh D; Singh PK; Maji SK Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727 [TBL] [Abstract][Full Text] [Related]
8. Mutations associated with familial Parkinson's disease alter the initiation and amplification steps of α-synuclein aggregation. Flagmeier P; Meisl G; Vendruscolo M; Knowles TP; Dobson CM; Buell AK; Galvagnion C Proc Natl Acad Sci U S A; 2016 Sep; 113(37):10328-33. PubMed ID: 27573854 [TBL] [Abstract][Full Text] [Related]
9. Structures and free energy landscapes of the A53T mutant-type α-synuclein protein and impact of A53T mutation on the structures of the wild-type α-synuclein protein with dynamics. Coskuner O; Wise-Scira O ACS Chem Neurosci; 2013 Jul; 4(7):1101-13. PubMed ID: 23607785 [TBL] [Abstract][Full Text] [Related]
10. Effects of Parkinson's disease-linked mutations on the structure of lipid-associated alpha-synuclein. Bussell R; Eliezer D Biochemistry; 2004 Apr; 43(16):4810-8. PubMed ID: 15096050 [TBL] [Abstract][Full Text] [Related]
11. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Conway KA; Harper JD; Lansbury PT Biochemistry; 2000 Mar; 39(10):2552-63. PubMed ID: 10704204 [TBL] [Abstract][Full Text] [Related]
12. The α-synuclein hereditary mutation E46K unlocks a more stable, pathogenic fibril structure. Boyer DR; Li B; Sun C; Fan W; Zhou K; Hughes MP; Sawaya MR; Jiang L; Eisenberg DS Proc Natl Acad Sci U S A; 2020 Feb; 117(7):3592-3602. PubMed ID: 32015135 [TBL] [Abstract][Full Text] [Related]
13. Copper Binding and Subsequent Aggregation of α-Synuclein Are Modulated by N-Terminal Acetylation and Ablated by the H50Q Missense Mutation. Mason RJ; Paskins AR; Dalton CF; Smith DP Biochemistry; 2016 Aug; 55(34):4737-41. PubMed ID: 27517125 [TBL] [Abstract][Full Text] [Related]
14. The H50Q mutation induces a 10-fold decrease in the solubility of α-synuclein. Porcari R; Proukakis C; Waudby CA; Bolognesi B; Mangione PP; Paton JF; Mullin S; Cabrita LD; Penco A; Relini A; Verona G; Vendruscolo M; Stoppini M; Tartaglia GG; Camilloni C; Christodoulou J; Schapira AH; Bellotti V J Biol Chem; 2015 Jan; 290(4):2395-404. PubMed ID: 25505181 [TBL] [Abstract][Full Text] [Related]
15. Arylsulfatase A, a genetic modifier of Parkinson's disease, is an α-synuclein chaperone. Lee JS; Kanai K; Suzuki M; Kim WS; Yoo HS; Fu Y; Kim DK; Jung BC; Choi M; Oh KW; Li Y; Nakatani M; Nakazato T; Sekimoto S; Funayama M; Yoshino H; Kubo SI; Nishioka K; Sakai R; Ueyama M; Mochizuki H; Lee HJ; Sardi SP; Halliday GM; Nagai Y; Lee PH; Hattori N; Lee SJ Brain; 2019 Sep; 142(9):2845-2859. PubMed ID: 31312839 [TBL] [Abstract][Full Text] [Related]
16. Membrane interactions of oligomeric alpha-synuclein: potential role in Parkinson's disease. van Rooijen BD; Claessens MM; Subramaniam V Curr Protein Pept Sci; 2010 Aug; 11(5):334-42. PubMed ID: 20423294 [TBL] [Abstract][Full Text] [Related]
17. Functional Study of SNCA p.V15A Variant: Further Linking α-Synuclein and Glucocerebrosidase. Avenali M; Cerri S; Palmieri I; Ongari G; Stiuso R; Buongarzone G; Tassorelli C; Biagini T; Valente M; Cereda C; Mazza T; Gana S; Pacchetti C; Valente EM Mov Disord; 2024 Jun; 39(6):1060-1065. PubMed ID: 38436488 [TBL] [Abstract][Full Text] [Related]
18. The Role of Lipids Interacting with α-Synuclein in the Pathogenesis of Parkinson's Disease. Galvagnion C J Parkinsons Dis; 2017; 7(3):433-450. PubMed ID: 28671142 [TBL] [Abstract][Full Text] [Related]
19. Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of α-synuclein. Rutherford NJ; Moore BD; Golde TE; Giasson BI J Neurochem; 2014 Dec; 131(6):859-67. PubMed ID: 24984882 [TBL] [Abstract][Full Text] [Related]
20. Oligomers of Parkinson's Disease-Related α-Synuclein Mutants Have Similar Structures but Distinctive Membrane Permeabilization Properties. Stefanovic AN; Lindhoud S; Semerdzhiev SA; Claessens MM; Subramaniam V Biochemistry; 2015 May; 54(20):3142-50. PubMed ID: 25909158 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]